Page 838 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

816 Index

Canine osteosarcoma (Continued) Canine ovarian tumors, 597–598 Canine transmissible venereal tumors
(CTVTs), 781
history and clinical signs in, 528 epithelial tumors and, 597 dendritic cells and, 233–234
systemic alterations, 528
germ cell tumors and, 598
VetBooks.ir incidence and risk factors for, 524 history and clinical signs of, 598 diagnostic techniques and workup, 783
mesenchymal tumors as, 598
limb salvage, nonsurgical, 539–542
history and clinical signs, 782, 783f–784f
intracorporeal and extracorporeal radiograph of, 598f incidence and risk factors, 781
intraoperative radiation therapy in, sex cord stromal tumors and, 597–598 pathology and natural behavior, 781–782
539 Canine penile, preputial, and scrotal tumor prognosis, 784
isolation of limb circulation and classification of, 636–637 therapy, 783–784
perfusion in, 540 signs of, 636–637 Canine urinary bladder tumors, 645–652, 645f
stereotactic radiation therapy in, Canine pituitary-dependent hypercortisolism, diagnosis of, 646–648, 647f–648f
539–540, 539f–540f treatment of, 567–568 differential diagnosis of, 646–648
summary of outcome after, 540–541 Canine prostate tumor, 631 etiology of, 645–646, 646t
molecular targeted therapies for, 545–546 cause of, 632 presentation of, 646–648
palliative treatment for, 547–549 cyclooxygenase-2 (COX-2) expression and, prevention of, 645–646
aminobisphosphonates in, 548–549 632 prognosis for, 652
palliative radiation therapy in, 547 diagnosis and staging of, 633–634, 633f–634f staging of, 646–648
radiopharmaceuticals in, 547–548 history and clinical signs of, 632 TNM staging for, 646b
pathology and natural behavior in, incidence/prevalence of, 631 transitional cell carcinoma cells and, 645
527–528, 527f mineralization and, 633, 633f treatment of
prognostic factors for, 531–534 natural behavior of, 632 localized therapy, 651
anatomic location and signalment, pathogenesis, 632 radiation therapy, 649
531–532 prognosis for, 634–636 surgery, 648–649
molecular, genetic, and immunologic risk factors for, 631 systemic medical therapy, 649–651,
indices of, 533–534 treatment of, 634–636 649t–650t
serum alkaline phosphatase in, 532–533, palliative options, 634–635 Canine uterine tumor, pathology and natural
532f with radiation therapy, 635, 635f behavior of, 600
radiation therapy for, 541–542 systemic therapy, 634 CANR. see California Animal Neoplasm
radioisotopes for, 542 with urethral obstruction, 634–635 Registry
radiology for, 528–529 Canine pulmonary lymphomatoid Carbimazole, for feline hyperthyroidism,
staging and patient assessment for, 529–531 granulomatosis, 514 578–579
bone survey radiography in, 531 Canine sinonasal tumors, 494 Carbohydrates, periodic acid-Schiff (PAS)
surgical, 531 biopsy of, 498f stain, 129
systemic, 529–531, 531f diagnosis for, 495–498, 496f–498f, 498t Carboplatin, 196–197
surgery for, 534–538, 535t contrast-enhanced CT of, 496f for canine osteosarcoma, 543t
allograft limb salvage, 535–537, 537f history and clinical signs of, 495 clinical use of, 196
amputation in, 534, 536f incidence and risk factors of, 494 myelotoxicity and PK of, 188–189
limb salvage in, 534–538 pathology and natural behavior of, 495 neutrophil nadir and, 189f
longitudinal bone transport osteogenesis prognosis of, 498–503 pharmacology of, 196
in, 537–538, 538f radiation therapy for, 495–496 Carcinoembryonic antigen (CEA), 239–240
metal endoprosthesis in, 537, 538f effects of, 499, 499f Carcinogen
nonappendicular and less common intensity-modulated, 500 chemical
appendicular sites of, 541, 541f response to, 499 cyclophosphamide, 15
ulnar transposition in, 538 staging for, 495–498 environmental tobacco smoke, 14
systemic adjuvant therapy for, 542–545 treatment for, 498–503, 499f–500f pesticides, herbicides, and insecticides, 15
chemotherapy in, 542–544, 543t chemotherapy for, 501–502 hormonal factors, 17–19, 17t
conventional chemotherapy combined Canine squamous papilloma, 675 ionizing radiation as, 212
with metronomic therapies in, 544 Canine testicular tumor, 626–630 physical
doxorubicin-carboplatin alternating cell lineages of, 626 asbestos, 17
chemotherapy in, 543 characteristics of, 627t implanted devices, 17
doxorubicin-carboplatin combined classification of, 626 magnetic fields, 16
chemotherapy in, 542–543 comparative aspects of, 631 sunlight, 16
doxorubicin-carboplatin modified diagnosis and staging of, 629–630, 630f trauma/chronic inflammation, 16
combination sequencing or dose history and clinical signs of, 629, 629f report on, 13–14
interval in, 543–544 hormone levels in, 628–629 rural versus urban environment and, 15–16
head-to-head comparison studies in, 544 metastasis of, 629 Carcinogenesis
immunotherapy in, 544–545 natural behavior of, 628–629 growth factor receptors and, 41
single-agent carboplatin chemotherapy pathogenesis of, 627–628 growth factors and, 41
in, 542 pathology of, 627–628 metastatic phenotype and, 55
single-agent doxorubicin chemotherapy prevalence/incidence of, 626 protein kinases and, 42
in, 542 risk factors for, 626–627, 627f smoking and, 92
tissue biopsy for, 529, 530f treatment and prognosis for, 630 steps in, 40